Published in Mol Pharmacol on May 01, 1983
S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A (1992) 5.37
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39
Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest (1992) 2.14
A molecular basis for nitric oxide sensing by soluble guanylate cyclase. Proc Natl Acad Sci U S A (1999) 1.86
N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest (1985) 1.57
NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest (1993) 1.44
Polynitrosylated proteins: characterization, bioactivity, and functional consequences. Proc Natl Acad Sci U S A (1996) 1.25
The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol (1990) 1.11
S-nitrosothiol-modified dendrimers as nitric oxide delivery vehicles. Biomacromolecules (2008) 1.08
Nos3 protects against systemic inflammation and myocardial dysfunction in murine polymicrobial sepsis. Shock (2010) 1.05
Role of a copper (I)-dependent enzyme in the anti-platelet action of S-nitrosoglutathione. Br J Pharmacol (1996) 1.05
Copper chelation-induced reduction of the biological activity of S-nitrosothiols. Br J Pharmacol (1995) 0.97
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. Am J Physiol Heart Circ Physiol (2010) 0.93
Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiol Rev (2010) 0.92
Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine on human platelets. Br J Pharmacol (1994) 0.91
Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. West J Med (1991) 0.88
Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. Crit Care Res Pract (2012) 0.87
Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica (2013) 0.84
A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: sustained vascular response. Nitric Oxide (2012) 0.81
S-nitrosothiols as selective antithrombotic agents - possible mechanisms. Br J Pharmacol (2010) 0.81
Role of nitric oxide in progression and regression of atherosclerosis. West J Med (1996) 0.80
Potential Benefits of Peroxynitrite. Open Pharmacol J (2008) 0.78
Low-dose L-arginine administration increases microperfusion of hindlimb muscle without affecting blood pressure in rats. Proc Natl Acad Sci U S A (2007) 0.77
The Reemergence of Nitrite as a Beneficial Agent in the Treatment of Ischemic Cardiovascular Diseases. Asian J Exp Biol Sci (2010) 0.76
Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther (1981) 6.71
The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol (1985) 3.29
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature (1999) 3.20
Relationship between cyclic guanosine 3':5'-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J Pharmacol Exp Ther (1981) 3.14
Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res (1979) 3.11
Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke (1998) 3.03
Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther (1986) 2.64
Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med (1992) 2.56
Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol (1993) 2.53
Three-generation reproductive toxicity study of dietary bisphenol A in CD Sprague-Dawley rats. Toxicol Sci (2002) 2.37
Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta (1982) 2.00
Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms. J Biol Chem (1986) 1.86
Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. J Pharmacol Exp Ther (1984) 1.85
Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension (1991) 1.77
Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Can J Physiol Pharmacol (1981) 1.74
Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun (2001) 1.74
Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: possible involvement of S-nitrosothiols. Biochim Biophys Acta (1980) 1.74
Formation of free nitric oxide from l-arginine by nitric oxide synthase: direct enhancement of generation by superoxide dismutase. Proc Natl Acad Sci U S A (1994) 1.71
Differential selectivity of endothelium-derived relaxing factor and nitric oxide in smooth muscle. Br J Pharmacol (1987) 1.70
IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol (2000) 1.67
Bioregulation of lysosomal enzyme secretion from human neutrophils: roles of guanosine 3':5'-monophosphate and calcium in stimulus-secretion coupling. Proc Natl Acad Sci U S A (1975) 1.65
Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol (2000) 1.64
Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc Natl Acad Sci U S A (1982) 1.64
Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem (2000) 1.60
Hormonal control of lysosomal enzyme release from human neutrophils. Effects of autonomic agents on enzyme release, phagocytosis, and cylic nucleotide levels. J Exp Med (1974) 1.58
Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation. Proc Natl Acad Sci U S A (2001) 1.58
Co-induction of arginase and nitric oxide synthase in murine macrophages activated by lipopolysaccharide. Biochem Biophys Res Commun (1995) 1.57
Nitric oxide and atherosclerosis. Nitric Oxide (2001) 1.57
In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation (2000) 1.55
Regulation of soluble guanylate cyclase activity by porphyrins and metalloporphyrins. J Biol Chem (1984) 1.55
Prostaglandins as modulators of the autonomic nervous system. Fed Proc (1974) 1.54
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther (2001) 1.54
Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol (1996) 1.50
Nitric oxide synthase from cerebellum catalyzes the formation of equimolar quantities of nitric oxide and citrulline from L-arginine. Biochem Biophys Res Commun (1992) 1.50
Assessment of the reproductive and developmental toxicity of pesticide/fertilizer mixtures based on confirmed pesticide contamination in California and Iowa groundwater. Fundam Appl Toxicol (1994) 1.49
Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res (1993) 1.48
Influence of acetylcholine on contractile force and cyclic nucleotide levels in the isolated perfused rat heart. J Pharmacol Exp Ther (1973) 1.48
Hormonal control of lysosomal enzyme release from human neutrophils: elevation of cyclic nucleotide levels by autonomic neurohormones. Proc Natl Acad Sci U S A (1974) 1.48
Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine. Biochem Biophys Res Commun (1992) 1.46
In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation (2001) 1.46
Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol (2000) 1.45
Conversion of nitroxyl (HNO) to nitric oxide (NO) in biological systems: the role of physiological oxidants and relevance to the biological activity of HNO. Biochem Biophys Res Commun (1993) 1.44
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med Res Rev (2001) 1.43
Role of L-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol (1992) 1.41
Vascular smooth muscle-derived relaxing factor (MDRF) and its close similarity to nitric oxide. Biochem Biophys Res Commun (1990) 1.41
Evaluation of the developmental toxicity of methacrylamide and N,N'-methylenebisacrylamide in Swiss mice. Toxicol Sci (1998) 1.40
Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A (2001) 1.39
Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A (1992) 1.39
Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. Arch Biochem Biophys (1982) 1.38
Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience (1994) 1.36
Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. FEBS Lett (1980) 1.36
Enzyme release from polymorphonuclear leukocyte lysosomes: regulation by autonomic drugs and cyclic nucleotides. Science (1973) 1.34
The cause of acute congestive lesions of the lung. J Thorac Cardiovasc Surg (1967) 1.34
Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. Proc Natl Acad Sci U S A (1996) 1.32
Coronary arterial relaxation and guanylate cyclase activation by cigarette smoke, N'-nitrosonornicotine and nitric oxide. J Pharmacol Exp Ther (1980) 1.31
Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. J Immunol (1993) 1.30
Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun (1989) 1.29
A spectrophotometric assay for nitrate using NADPH oxidation by Aspergillus nitrate reductase. Anal Biochem (1993) 1.29
Pyrrolidine dithiocarbamate inhibits induction of nitric oxide synthase activity in rat alveolar macrophages. Biochem Biophys Res Commun (1993) 1.29
Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med (2000) 1.28
Endothelium-derived nitric oxide relaxes nonvascular smooth muscle. Eur J Pharmacol (1989) 1.27
Nonphagocytic release of neutral protease and beta-glucuronidase from human neutrophils. Regulation by autonomic neurohormones and cyclic nucleotides. Arthritis Rheum (1974) 1.27
Potentiation of adrenergic venomotor responses by angiotensin, prostaglandin F 2 and cocaine. J Pharmacol Exp Ther (1971) 1.26
Nitric oxide-cyclic GMP signal transduction system. Methods Enzymol (1996) 1.23
Relaxation of intrapulmonary artery and vein by nitrogen oxide-containing vasodilators and cyclic GMP. J Pharmacol Exp Ther (1984) 1.23
Relationships among digital clubbing, disease severity, and serum prostaglandins F2alpha and E concentrations in cystic fibrosis patients. Am Rev Respir Dis (1978) 1.22
Lipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW 264.7 macrophages. J Biol Chem (2001) 1.22
Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J Biol Chem (1996) 1.21
Differences in responsiveness of intrapulmonary artery and vein to arachidonic acid: mechanism of arterial relaxation involves cyclic guanosine 3':5'-monophosphate and cyclic adenosine 3':5'-monophosphate. J Pharmacol Exp Ther (1985) 1.20
Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol (2001) 1.18
Breakdown of noncollagenous chondromucoprotein matrix by leukocyte lysosome granule lysates from guinea pig, rabbit, and human. Clin Immunol Immunopathol (1973) 1.18
NG-methyl-L-arginine causes endothelium-dependent contraction and inhibition of cyclic GMP formation in artery and vein. Proc Natl Acad Sci U S A (1990) 1.17
Neutral protease release from human leukocytes regulated by neurohormones and cyclic nucleotides. Nat New Biol (1973) 1.16
Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci U S A (1999) 1.16
A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol (2000) 1.16
Mediation of immunologic discharge of lysosomal enzymes from human neutrophils by guanosine 3',5'-monophosphate. Requirement of calcium, and inhibition by adenosine 3',5'-monophosphate. J Exp Med (1974) 1.15
An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc Natl Acad Sci U S A (2001) 1.14